Everolimus for the Treatment of Uveitis Unresponsive to Cyclosporine A

Overview

Study efficacy of everolimus on course of uveitis: * obtain quiescence of inflammation after start of treatment * duration to obtain quiescence of inflammation * number of patients with quiescence of inflammation

occurence of new complications from uveitis * course of visual acuity (LogMAR): percentage of patients with visual loss of 10 or more numbers on ETDRS as compared to baseline * change of recurrence rate as compared to time before everolimus treatment * occurence of recurrence after obtaining remission with everolimus treatment * duration to occurence of recurrence o number of patients with recurrence * corticosparing effect from everolimus * number of patients without topical corticosteroids; number of patients with reduced topical corticosteroids (\<3x/daily) * number of patients without systemic corticosteroids; number of patients with reduced systemic corticosteroids (\<10mg/daily) * efficacy of uveitis within 12 months * maintenance of remission after withdrawel of everolimus treatment at 12 months o course of cystoid macula edema (FLA, OCT)

Conditions

Interventions

Eligibility

Locations (1)

Outcomes